Products | PET-CT | October 05, 2016

Discovery MI

Discovery MI

Related Content

Registration is now open for #ASTRO24
News | ASTRO
American Society for Radiation Oncology (ASTRO) to Host Annual Meeting in Washington, DC, Sept. 29-Oct. 2

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
New 10-year strategic agreement builds on 40-year collaboration history
News | Radiology Business
University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
SunCHECK Version 5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI.
News | Radiation Therapy
Sun Nuclear Announces Landmark Update to Further Advance Radiation Therapy Workflows

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
CDL now offers three solutions for cardiovascular imaging needs
News | Cardiac Imaging
CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 10, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients
News | Radiopharmaceuticals and Tracers
PanTera signs agreement with Bayer for the supply of actinium-225

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now